Drug-eluting stents in vascular intervention

Lancet

Volumn 361, Issue 9353, 2003, Pages 247-249

  Fattori, Rossella ^a   Piva, Tommaso ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANGIOPEPTIN; ARGININE; CARDIOVASCULAR AGENT; HILOPROST; HIRUDIN; IMMUNOSUPPRESSIVE AGENT; POLYMER; STATIN; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; BRACHYTHERAPY; CARDIOVASCULAR PROCEDURES; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CORONARY ARTERY DISEASE; DRUG COATING; ELUTION; GENE THERAPY; GENE TRANSFER; HEALTH CARE COST; HEART SURGERY; IMPLANTATION; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; SHORT SURVEY; SMOOTH MUSCLE FIBER; STENT; TREATMENT FAILURE; TUMOR CELL;

EID: 0037452233     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12275-1     Document Type: Short Survey

References (22)

1. American Heart Association. 2002 heart and stroke statistical update. Dallas: American Heart Association, 2001.
2. Bennett M.R., O'Sullivan M. Mechanism of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther. 91:2001;149-166.
3. Poon M., Badimon J.J., Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet. 359:2002;619-622.
4. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
5. Serruys P.W., Kay P., Disco C., et al. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of meta-analysis of the Belgian Netherlands Stent Study (BENESTENT) I; BENESTENT II AND music Trials. J Am Coll Cardiol. 34:1999;1067-1074.
6. Topol E.J., Mark D.B., Lincoff A.M., et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicenter randomized trial. Lancet. 354:1999;2019-2024.
7. Moer R., Myreng Y., Mølstald P., et al. Stenting In Small Coronary Arteries (SISCA) Trial: a randomized comparison between balloon angioplasty and the heparin coated beStent. J Am Coll Cardiol. 38:2001;1598-1603.
8. Farb A., Weber D.K., Kolodgie F.D., et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 105:2002;2974-2980.
9. Vom Dahl J., Dietz U., Haager P., et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial (ARTIST). Circulation. 105:2002;583-588.
10. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER Study). Circulation. 100:1999;799-806.
11. Holmes D., Savage M., La Blanche J.-M., et al. Results of Prevention REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 106:2002;1243-1250.
12. Leon B.M., Teirstein P.S., Moses J.W., et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 344:2001;250-256.
13. Waksman R, Raizner A3 Yeung AC, et al, for the INHIBIT Investigators. Use of localized intracoronary beta-radiation in treatment of in-stent restenosis: the INHIBIT randomized controlled trial. Lancet 2002; 359: 551-57.
14. Grise M.A., Massullo V., Jani S., et al. Five year clinical follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation. 105:2002;2737-2740.
15. Schwartz R.S., Edelman E. Drug-eluting stents in preclinical studies: recommendend evaluation from a consesus group. Circulation. 106:2002;1867-1873.
16. Klugherz B.D., Llanos G., Lieuallen W., et al. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus eluting stent. Coron Artery Dis. 13:2002;183-188.
17. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 346:2002;1773-1780.
18. Degertekin M., Serruys P.W., Foley D.P., et al. Persistent inhibition if neontimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 106:2002;1610-1613.
19. Liistro F., Stankovic G., Di Mario C., et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis. Circulation. 105:2002;1883-1886.
20. Virmani R., Liistro F., Stankovic G., et al. Mechanism of late in stent restenosis after implantation of a paclitaxel derivate eluting-stent system in humans. Circulation. 106:2002;2649-2651.
21. Morneault J.A., Kereiakes D.J., Wright C.B. Economic impact of drug eluting stents in a multiple hospital healtcare system. Am J Cardiol. 90:(6-I):2002;1H-4H.
22. Gruntzig A. Transluminal dilatation of coronary artery stenosis. Lancet. 1:1978;263.